Mid-Year Report

WINSTON TAYLOR LLP (FORMERLY KNOWN AS WINSTON & STRAWN LLP) for BARR LABORATORIES INC

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

authorized generics (H.R. 806; S.1082); patent reform legislation (H.R. 1908 and S.1145); FDA reform and regulation, and the federal drug approval process for generic drugs (S.1082; H.R. 2900); appropriations for the FDA Office of Generic Drug Approval (H.R. 3161; S.1859); procedures for drug approval harmonization in prospective trade agreements. Development of a biogeneric drug approval framework (S.1695; H.R. 1956); Issues affecting pharmaceuticals, including: Settlements legislation, S.316; opposition to legislation proposing patent filing deadline extensions, H.R. 1778 and various Senate amendments;

LobbyistCovered position, as disclosed
WESLEY BIZZELL N/A
CHARLES L KINNEY N/A
JOHN D MCMICKLE N/A
JOHN A WAITS N/A

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 316 (110th), H.R. 1908 (110th), S. 1859 (110th), S. 1695 (110th), H.R. 1956 (110th), H.R. 806 (110th), H.R. 2900 (110th), H.R. 1778 (110th), S. 1082 (110th), S. 1145 (110th), H.R. 3161 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.